CenterBook Partners
GPCR icon

CenterBook Partners’s Structure Therapeutics GPCR Stock Holding History

CenterBook Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-148,030
Closed -$7.94M – 937
2026
Q2 		$7.94M Buy
148,030
+126,793
+597% +$5.61M 0.39% 56
2026
Q1 		$1.02M Buy
+21,237
New +$1.45M 0.06% 349

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return
Peregrine Capital Management
Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

CenterBook Partners's GPCR Position: Q3 2026 in Review

CenterBook Partners sold out of Structure Therapeutics (GPCR) in Q3 2026, closing a stake of 148,030 shares — an estimated $7.94M sold.

CenterBook Partners first reported a position in GPCR in Q1 2026 and held it in 2 quarters. The position peaked at $7.94M in Q2 2026. 67 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • CenterBook Partners reported no remaining Structure Therapeutics position as of Q3 2026 after selling out during the quarter.
  • CenterBook Partners sold 148,030 Structure Therapeutics shares in Q3 2026, an estimated $7.94M.
  • CenterBook Partners first reported a position in Structure Therapeutics in Q1 2026 and held it in 2 quarters.
  • CenterBook Partners's Structure Therapeutics position peaked at $7.94M in Q2 2026.
  • 67 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.